30 completed, 20 recruiting, 16 terminated, 15 active not recruiting. 50 Phase 1, 43 Phase 2, 4 Early Phase 1, 3 Phase 3.
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma | Active not recruiting | Andrés José Maria Ferreri | 150 | 2025-12-10 | 2026-02-06 | |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-10-07 | 2026-10-21 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | University of California, Davis | 34 | 2025-08-07 | 2026-07-08 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| Epcoritamab-CAR T Cells for Large B-cell Lymphomas Epcoritamab - Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 31 | 2024-09-24 | 2026-05-27 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2025-10-20 |
| Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma RC19D2 cell injection - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Recruiting | Beijing Yongtai Ruike Biotechnology Company Ltd | 25 | 2023-09-05 | 2024-08-27 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Recruiting | City of Hope Medical Center | 9 | 2023-07-20 | 2026-02-04 |
Showing 20 of 91. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (91) · Lymphoma, Follicular (22) · Lymphoma, Mantle-Cell (22) · Lymphoma, Non-Hodgkin (16) · Lymphoma, B-Cell (15) · Lymphoma, B-Cell, Marginal Zone (14) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Burkitt Lymphoma (9) · Lymphoma (5) · Neoplasms (5) · Hodgkin Disease (4) · Lymphoma, T-Cell (4) · Recurrence (4) · Multiple Myeloma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)
Hemic and Lymphatic Diseases (91) · Immune System Diseases (89) · Immunoproliferative Disorders (89) · Lymphatic Diseases (89) · Lymphoproliferative Disorders (89) · Neoplasms by Histologic Type (89) · Lymphoma (86) · Neoplasms (86) · Lymphoma, B-Cell (76) · Lymphoma, Non-Hodgkin (75) · Hematologic Diseases (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Disease Attributes (18) · Leukemia (15)
Rituximab (24) · Magnetic Resonance Spectroscopy (20) · Specimen Handling (17) · CT-P10 (16) · Cyclophosphamide (15) · Biopsy (12) · Etoposide (11) · fludarabine (11) · Lenalidomide (10) · ibrutinib (10) · Carboplatin (9) · Leukapheresis (9) · Gemcitabine (8) · Ifosfamide (8) · Nivolumab (8)
City of Hope Medical Center (11) · National Cancer Institute (NCI) (11) · Fred Hutchinson Cancer Center (8) · M.D. Anderson Cancer Center (6) · University of Washington (5) · University of California, Davis (3) · BeiGene (2) · David Bond, MD (2) · Jonsson Comprehensive Cancer Center (2) · Mayo Clinic (2) · Roswell Park Cancer Institute (2) · Rutgers, The State University of New Jersey (2) · SWOG Cancer Research Network (2) · University of Nebraska (2) · ADC Therapeutics S.A. (1)
United States (80) · China (7) · United Kingdom (5) · Spain (4) · Canada (3) · France (3) · Germany (3) · Italy (3) · Australia (2) · Belgium (2) · Hungary (2) · New Zealand (2) · Poland (2) · Argentina (1) · Austria (1)
Alex F Herrera (3) · Jordan Gauthier (3) · David Bond, MD (2) · Joseph M Tuscano (2) · Kami Maddocks, MD (2) · Stephen D. Smith (2) · Yago L Nieto (2) · Ajay Gopal (1) · Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Alexey Danilov (1) · Amrita Y. Krishnan MD, MD (1) · Andre Goy, MD (1) · Andy Davies (1)
PMID 34515338, PMID 27111235, PMID 29038338, PMID 29386196, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31331917, PMID 31648294, PMID 32967009, PMID 33786583, PMID 33942298, PMID 34435552, PMID 34666344, PMID 36618900, PMID 36631449, PMID 37300573, PMID 37339586, PMID 37470137, PMID 37632592, PMID 37774014, PMID 37903325, PMID 39333103, PMID 39352751, PMID 39820359, PMID 41595202, PMID 41845899, PMID 42389828
P30CA033572 (6), P30CA093373 (3), P50CA107399 (3), UM1CA186709 (3), P30CA015704 (2), P30CA016058 (2), P30CA016672 (2), P30CA036727 (2), P30CA072720 (2), R01CA136551 (2), U10CA180888 (2), UM1CA186644 (2), UM1CA186686 (2), UM1CA186717 (2), 2016 (1)